PSA Use and Incidence of Prostate Biopsy in the Tuscany Region: Is Opportunistic Screening Discounting Biopsy in Subjects with PSA Elevation?

Author:

Ciatto Stefano1,Houssami Nehmat12,Martinelli Francesca1,Giusti Francesco1,Zappa Marco1

Affiliation:

1. CSPO, Istituto Scientifico per la Prevenzione Oncologica, Florence, Italy

2. Screening and Test Evaluation Program (STEP), School of Public Health, University of Sydney, Sydney, Australia

Abstract

Aims and Background To assess PSA use in the general population and estimate biopsy rate subsequent to opportunistic screening. Methods and Study Design We report on PSA testing and related prostate biopsy frequency in the Tuscany Region during 2004–2005 to establish current patterns of care. We used population data sources to survey PSA testing and biopsy and estimated expected PSA values and expected recommended biopsies (≥PSA 4 ng/ml) from the ongoing Florence arm of the European Study of Screening for Prostate Cancer (ERSPC). Results PSA testing was common for both years and across age groups, increasing with age and peaking at 70–74 years (37.6% in 2004, 41.9% in 2005) and increasing over the 2 years. PSA use in the 55–69 years cohort (screening age in ERSPC) was 28.3% in 2004 and 30.4% in 2005. Repeat PSA testing was also common and repeat PSA probability increased with age, peaking at age 70–74 (60.9%); repeat PSA testing at age 55–69 was 53.7%. Overall, 1.3% and 1.2% of men had a biopsy following PSA testing in 2004 and 2005. Observed/expected biopsy incidence was 14.3% in 2004 and 13.2% in 2005. ERSPC compliance to recommended biopsy was 77% or 60% at first or repeat screening. Conclusions A discordance was identified between high PSA testing prevalence and low prostate biopsy rate. Based on projections from the ERSPC, this indicates a much lower observed biopsy rate than expected in organized screening. Although the implications of this are difficult to quantify in the absence of evidence on screening efficacy, it suggests inefficient practice.

Publisher

SAGE Publications

Subject

Cancer Research,Oncology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3